Upstream Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $152.79M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | $773.00K | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | Before market open | $1.03M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | $668.00K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $683.00K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $937.00K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $566.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | Before market open | $613.00K | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $607.00K | – | – |
Press releases
Announcements Upstream Bio filed with the SEC
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Results of operations · EX-99.1 to Form 8-K
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Top-line Results for the Phase 2
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress
Results of operations · EX-99.1 to Form 8-K
Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Results of operations · EX-99.1 to Form 8-K
Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
Results of operations · EX-99.1 to Form 8-K
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K